The MEF2D::NCOA2 Fusion Defines a Distinct Emerging Vulvovaginal Myxoid Epithelioid Tumor With Smooth Muscle Differentiation
Modern Pathology · 2025
DOI: 10.1016/j.modpat.2025.100750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Alexis Trecourt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Pathologie Multi-Site, Pierre-Bénite, France; Université Claude Bernard Lyon-1, Facu…. Hauptthemen laut MEDLINE: Nuclear Receptor Coactivator 2, Vulvar Neoplasms, MEF2 Transcription Factors, Vaginal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospices Civils de Lyon.
Abstract (Originalsprache)
Myocyte-specific enhancer factor 2D gene and nuclear receptor coactivator 2 gene fusion (MEF2D::NCOA2) was recently reported in 2 vulvovaginal myxoid epithelioid smooth muscle tumors. We aimed to perform an integrated approach combining clinical, morphologic, immunohistochemical, and molecular profiling analyses, including targeted RNA sequencing, targeted gene expression analysis profiling with clustering, DNA mutational analysis, and array comparative genomic hybridization in a series of 3 MEF2D::NCOA2 fusion-associated vulvovaginal tumors, to better describe this entity. The median age at diagnosis was 45 years. Tumors were well circumscribed and located deeply within the vulva, vaginal wall, or between the bladder and the vagina (1/3, 33.3% each). The median size of tumors was 2.5 cm. All tumors had a similar morphology, reminiscent of smooth muscle tumor with prominent myxoid stromal changes (3/3, 100%). Tumor cells were haphazardly arranged in short fascicles and were mostly spindle cells. Microcystic spaces lined by epithelioid cells and/or sheets of epithelioid cells were observed in all tumors (3/3, 100%), associated with a myxoid background. Cytologic atypia was none to mild, and the mitotic counts were always low (≤1 mitosis/high-power fields). Immunohistochemistry found smooth muscle actin, desmin, h-caldesmon, estrogen receptors, and CD34 to be intensely and diffusely expressed in all tumors (3/3, 100%). A MEF2D::NCOA2 transcript was observed in all tumors (3/3, 100%), which was the driver of molecular alteration. No pathogenic variants were found, and array comparative genomic hybridization found simple genomic profiles for all tumors (3/3, 100%). On targeted gene expression analysis, MEF2D::NCOA2 fusion-associated tumors clustered distinctly from other gynecologic mimickers and neoplasms with myxoid stromal changes (vulvovaginal leiomyomas, myxoid vulvovaginal leiomyomas, deep angiomyxomas, myxoid leiomyosarcomas, myxoid endometrial stromal sarcomas, and inflammatory myofibroblastic tumors). The signaling pathways involved in this entity included the expression of genes encoding smooth muscle phenotype proteins, favoring a smooth muscle (myoid) differentiation. All patients were alive and free of disease at the last follow-up. To conclude, vulvovaginal MEF2D::NCOA2 fusion-associated tumors are distinct and emerging entities, with a rather indolent behavior.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Pathologie Multi-Site, Pierre-Bénite, France; Université Claude Bernard Lyon-1, Faculté de Médecine Lyon Sud, Centre pour l'innovation en cancérologie de…
- Institut Universitaire du Cancer Toulouse Oncopole, Service de Pathologie, Toulouse, France.
- Institut Bergonié, Service de Pathologie, Bordeaux, France; Université de Bordeaux, BRIC, Bordeaux, France.
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Pathologie Multi-Site, Pierre-Bénite, France; Université Claude Bernard Lyon-1, Centre International de Recherche en Infectiologie (CIRI), Institut Nation…
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Pathologie Multi-Site, Pierre-Bénite, France.
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Biochimie et de Biologie Moléculaire, Pierre-Bénite, France.
Förderung
- Hospices Civils de Lyon
Zitieren
APA
Trecourt, A., Bataillon, G., Le Loarer, F., Donzel, M., Alix, E., Descotes, F., Lopez, J., Thamphya, B., Pissaloux, D., Treilleux, I., Croce, S., & Devouassoux-Shisheboran, M. (2025). The MEF2D::NCOA2 Fusion Defines a Distinct Emerging Vulvovaginal Myxoid Epithelioid Tumor With Smooth Muscle Differentiation. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100750
Vancouver
Trecourt A, Bataillon G, Le Loarer F, Donzel M, Alix E, Descotes F, et al. The MEF2D::NCOA2 Fusion Defines a Distinct Emerging Vulvovaginal Myxoid Epithelioid Tumor With Smooth Muscle Differentiation. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100750
BibTeX
@article{Trecourt2025,
author = {Trecourt, Alexis and Bataillon, Guillaume and Le Loarer, François and Donzel, Marie and Alix, Eudeline and Descotes, Françoise and Lopez, Jonathan and Thamphya, Brice and Pissaloux, Daniel and Treilleux, Isabelle and Croce, Sabrina and Devouassoux-Shisheboran, Mojgan},
title = {The MEF2D::NCOA2 Fusion Defines a Distinct Emerging Vulvovaginal Myxoid Epithelioid Tumor With Smooth Muscle Differentiation},
journal = {Modern Pathology},
year = {2025},
doi = {10.1016/j.modpat.2025.100750}
}
EUVIMED